GH Receptor Antagonists: Basic Knowledge and Clinical Perspectives
Author:
van der Lely A. J.
Reference45 articles.
1. Abdel-Meguid S.S., Shieh H.S., Smith W.W., Dayringer H.E., Violand B.N. and Bentie L.A. (1987). Three-dimensional structure of a genetically engineered variant of porcine growth hormone. Proc Natl Acad Sci USA 84, 6434–6437. 2. Bellush L.L., Doublier S., Holland A.N., Striker L.J., Striker G.E. and Kopchick J.J. (2000). Protection against diabetes-induced nephropathy in growth hormone receptor/binding protein gene-disrupted mice. Endocrinology, 141, 163–168. 3. Carter-Su C, Rui L. and Herrington J. (2000). Role of the tyrosine kinase JAK2 in signal transduction by growth hormone. Pediatr Nephrol, 14, 550–557. 4. Chan J.M., Stampfer M.J., Giovannucci E., Gann P.H., Ma J., Wilkinson P., Hennekens C.H. and Pollak M. (1998). Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science, 279, 563–566. 5. Chen N.Y., Chen W.Y., Bellush L., Yang C.W., Striker L.J., Striker G.E. and Kopchick J.J. (1995). Effects of streptozotocin treatment in growth hormone (GH) and GH antagonist transgenic mice. Endocrinology, 136, 660–667.
|
|